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J PIntroduction: Fecal immunochemical testing (FIT) is an attractive approach for colorectal cancer
screening at community health centers. This budget impact analysis investigated beneﬁts and costs
of FIT outreach—with FIT kits mailed to patients, followed by reminders and phone calls—
compared with point-of-care (POC) strategies.
Methods: Five screening and cost outcomes were simulated over 1 year at a “base case” community
health center serving 1000 screening-eligible patients: (1) FIT completion among patients due for
screening; (2) proportion up-to-date on screening; (3) cost per patient due for screening; (4) cost per
completed FIT; and (5) total organizational cost. Uncertainty analysis investigated potential savings
from optimizing staff workﬂows during FIT outreach. Data were collected in 2012–2014, with
analysis conducted 2014–2015.
Results: Using POC strategies, 24.0% of patients due for screening completed FIT, versus 42.4%
under outreach (18.4% absolute difference). When calculations included patients up-to-date on
screening from prior colonoscopy, 41.7% were up-to-date via POC, versus 55.8% for outreach
(14.1% absolute difference). POC cost $4.93 per patient, versus $30.43 for outreach ($25.50
difference). Cost per patient screened was $20.60 for POC and $71.84 for outreach ($51.24
difference). Total organizational cost was $3,779 for POC distribution and $23,315 for outreach
($19,536 difference). Outreach costs decreased by approximately one fourth under optimized
workﬂows.
Conclusions: Outreach is an effective, practical, relatively low-cost strategy; costs could be reduced
further by optimizing staff workﬂows. Despite its value, outreach costs more than POC distribution
and may be difﬁcult for community health centers to implement under current payment models.
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open access article under the CC BY-NCIntroductionScreening for colorectal cancer (CRC) is effective,
1–6
cost effective,7 and potentially cost saving in the
context of preventing future cancer care costs.8
Nevertheless, less than two thirds of Americans aged
50–75 years are up-to-date on CRC screening, and
screening rates are particularly low among racial/ethnic
minorities and the uninsured.9,10
Community health centers (CHCs) can play an
important role in addressing current screening dispar-
ities. Although CHCs typically do not offer onsite
endoscopy, providers can often deliver fecal occult blood
testing (FOBT). Multiple outreach strategies have been
shown to increase FOBT uptake, such as mailing FOBTnal of Preventive Medicine  Published by Elsevier Inc. This is an
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Liss et al / Am J Prev Med 2016;50(2):e54–e61e55kits to patients who are overdue for annual testing11–14
and patient reminders for FOBT.11,15 In addition, fecal
immunochemical testing (FIT), which has no dietary
restrictions and requires only one stool sample, increases
screening relative to guaiac-based FOBT.16,17
When balancing organizational priorities, CHC
administrators need detailed information on potential
beneﬁts and costs of interventions to increase CRC
screening. No prior studies have examined budgetary
impacts of CRC screening interventions in CHC settings.
To address this gap in the evidence, a budget impact
analysis was conducted that investigated the following
outcomes for an evidence-based FIT outreach program,
compared with usual care relying on point-of-care (POC)
strategies, at a CHC over 1 year:1.FebFIT completion among patients due for CRC
screening;2. the proportion of patients who are up-to-date on
screening;3. the cost per patient due for screening;
4. the cost per completed FIT; and
5.Figure 1. Flow chart of workﬂows in outreach program.
FIT, fecal immunochemical testing.total organizational cost.
Methods
This budget impact analysis was conducted in accordance with
guidelines from the International Society for Pharmacoeconomics
and Outcomes Research,18 using the perspective of a CHC
budgetary decision maker. Study data were collected in 2012–
2014; analysis was conducted in 2014–2015. Because CHCs
typically operate under an annual budget cycle, a 1-year time
horizon was used.
This study compared screening rates and costs for FIT programs
using POC distribution or outreach, which have been previously
described in detail.19 In the POC distribution program, if a patient
who attended a primary care ofﬁce visit was due for CRC
screening, a medical assistant (MA) provided counseling on
CRC screening and offered a FIT kit (sample collection bottle,
FIT test strips, and postage-paid return envelope) at the beginning
of the visit. In the outreach program, a screening navigator mailed
FIT kits when patients became due for annual screening; patients
receiving outreach who did not return the FIT at deﬁned intervals
received a series of automated reminders and phone calls over 3
months (Figure 1). After 3 months, patients reached by phone who
had not yet screened were offered a second mailed FIT kit.
Analyses were conducted in Microsoft Excel, version 14.0. Study
protocols were approved by Northwestern University’s IRB.
Screening rates and costs were projected over 1 year at a “base
case” CHC that—to a practical extent—was representative of
CHCs nationally. Published national data were used as the basis
of assumptions about the prior screening history (i.e., screening
behavior before implementation of POC distribution or outreach)
of patients at the base case CHC (Table 1). The authors assumed
30% of patients were up-to-date on screening in the prior year,
based on the national rate at Health Resources and Servicesruary 2016Administration–funded health centers.20 There are no published
national estimates of how often CHC patients complete screening
using FOBT versus colonoscopy. In the absence of such data, prior
usage of each screening modality was estimated based on report of
FOBT (14%) and endoscopy (86%) by uninsured Behavioral Risk
Factor Surveillance System respondents.10 Sigmoidoscopy was not
considered because it is rarely used by Americans.9,10
The authors assumed the base case CHC served 1,000 patients
who were eligible for CRC screening. Because patients who screen
via colonoscopy should do so every 10 years,6 it was assumed that
10% of patients who had completed prior colonoscopy would be
due for CRC screening over this study’s 1-year time horizon. It was
assumed that this group would complete FOBT at the same rate as
patients who had never screened, whereas the other 90% of patients
who had completed prior colonoscopy would remain up-to-date on
screening over 1 year and would not be targeted for screening (i.e.,
screening programs incurred $0 cost for these patients).
Assumptions about FIT completion in the POC distribution and
outreach programs were based on empirical ﬁndings from two
randomized trials the authors conducted at Erie Family Health
Center, a CHC based in Chicago IL (Table 1). The ﬁrst trial was
conducted in 2012–2014 among patients who had previously
completed FOBT and were due for repeat annual screening (“repeat
screening”). In the repeat screening trial, 37.3% of patients in the POC
group and 82.2% of patients in the outreach group completed FIT
within 6 months.22 The second trial was conducted in 2013–2014
Table 1. Data Used to Calculate Screening Rates for Point-of-Care and Outreach
Programs
Variable Base case, % Sources
CRC screening history
Probability that screening-eligible
patients are up-to-date on screening
at baseline
30 (range 15–60) Liss and Baker (2014)10,
HRSA (2012)20
Probability of prior colonoscopy versus FOBT, among patients up-to-date at baseline
Colonoscopy within past 10 years 86 (range 10–90) Liss and Baker (2014)10
FOBT within past year 14 (range 10–90) Liss and Baker (2014)10
Probability of FIT completion over 1 year
Patients who have never screened
Point-of-care distribution
r2 weeks 2.9 Goldman et al. (2015)21
42–13 weeks 4.8 Goldman et al. (2015)21
413–26 weeks 7.1 Goldman et al. (2015)21
426–52 weeks 7.6 Goldman et al. (2015)21
Total (1 year) 22.4 Goldman et al. (2015)21
Outreach Goldman et al. (2015)21
r2 weeks 13.8 Goldman et al. (2015)21
42–13 weeks 13.8 Goldman et al. (2015)21
413–26 weeks 9.1 Goldman et al. (2015)21
426–52 weeks 3.3 Goldman et al. (2015)21
Total (1 year) 40.0 Goldman et al. (2015)21
Patients due for repeat screening
Point-of-care distribution
r2 weeks 14.7 Baker et al. (2014)22
42–13 weeks 12.0 Baker et al. (2014)22
413–26 weeks 10.7 Baker et al. (2014)22
426–52 weeks 14.7 See text
Total (1 year) 52.0 See text
Outreach
r2 weeks 49.8 Baker et al. (2014)22
42–13 weeks 24.0 Baker et al. (2014)22
413–26 weeks 8.4 Baker et al. (2014)22
426–52 weeks 3.1 See text
Total (1 year) 85.3 See text
Probability patient receives FIT kit to complete at home
Patients who have never screened
(continued on next page)
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pleted CRC screening (“never
screened”). In the never screened
trial, 14.8% of POC patients and
36.7% of outreach patients completed
FIT within 6 months; within 1 year,
FIT was completed by 22.4% of POC
patients and 40.0% of outreach
patients.21
In both prior trials, the primary
outcome was FIT completion
within 6 months.19 Because of the
current study’s 1-year time horizon,
analyses also incorporated the fol-
lowing previously unpublished
ﬁndings from the repeat screening
trial: Between 6 and 12 months of
follow-up, 14.7% of patients in the
POC group and 3.1% of patients in
the outreach group completed FIT.
Among patients due for repeat
annual screening, the total FIT
completion rate over 1 year was
52.0% in the POC group and
85.3% in the outreach group (D
Baker, Northwestern University,
personal communication, 2014).
The authors made assumptions
about FIT distribution among POC
patients using empirical data from
their prior trials (Table 1). They
assumed patients in the outreach
program received a FIT kit, via mail,
to complete at home. They were
unable to track patients’ refusal of
FIT in the POC program, so FIT
distribution rates were derived for
POC patients by assuming that
POC patients who accepted a FIT
kit completed screening at the same
rate as outreach patients with the
same screening history (i.e., never
screened or repeat screening). POC
FIT distribution rates were then
calculated by dividing the propor-
tion of completed FITs in each POC
sample by the total return rate in
each respective outreach sample.
Based on empirical ﬁndings that
73% of POC patients in the never
screened trial and 93% of POC
patients in the repeat screening trial
had any ofﬁce visits during 1 year of
follow-up, it was assumed that
POC patients who had any ofﬁce
visits received one instance of MA
counseling, at which time they were
offered a FIT kit.www.ajpmonline.org
Table 1. Data Used to Calculate Screening Rates for Point-of-Care and Outreach
Programs (continued)
Variable Base case, % Sources
Point-of-care distribution 56 See text
Outreach 100 Goldman et al. (2015)21
Patients due for repeat screening
Point-of-care distribution 61 See text
Outreach 100 Baker et al. (2014)22
Probability patient receives MA counseling at ofﬁce visit (point-of-care distribution only)
Patients who have never screened 73 See text
Patients due for repeat screening 93 See text
Probability second FIT kit mailed at 13 weeks (outreach only)
Patients who have never screened 38 Goldman et al. (2015)21
Patients due for repeat screening 10 Baker et al. (2014)22
FIT test characteristics
Probability of negative test 89 Baker et al. (2014)22,
Goldman et al. (2015)21
Probability of positive test 11 Baker et al. (2014)22,
Goldman et al. (2015)21
CRC, colorectal cancer; FIT, fecal immunochemical test; FOBT, fecal occult blood testing; HRSA, Health
Resources and Services Administration; MA, medical assistant.
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completed FIT within 2 weeks were sent automated reminders at
that time. Empirical data on FIT distribution from each trial were
used to model the frequency that outreach patients were sent a
second FIT kit after speaking with the screening navigator at 13
weeks. Empirical trial data on positive and negative FIT results
were also used to determine the proportion of outreach patients
who completed FIT and were informed of a negative result by mail.
Published prices from a medical supply website23 were used to
estimate FIT kit costs (Table 2). Year 2015 U.S. Postal Service ﬁrst-
class postage rates were assumed, including a postage meter
discount. Costs of printed materials and automated reminders
were modeled using actual prices paid to a commercial printer and
digital reminder service during prior outreach trials (T Brown,
Northwestern University, personal communication, 2014).
Personnel costs for processing completed FITs and for POC
distribution were estimated by tracking staff efforts at the site of
the authors’ prior trials. Work by a lab technician to process
returned FIT specimens and documentation of test results in the
electronic health record was timed (6.5 minutes per returned FIT,
$16.20 hourly wage). MA work in the POC program was also
tracked by timing relevant patient conversations and documenta-
tion (2.0 minutes per patient, $14.00 hourly wage). It was not
possible to discretely track screening navigator work because
during the prior outreach trials, the screening navigator simulta-
neously delivered outreach and collected research data. Therefore,
the screening navigator estimated the full-time equivalent effort
associated with all outreach work, which was converted to minutesFebruary 2016(55.5 minutes per patient).
Although the screening navigator
in our prior trials was compensated
at a different level than MAs, out-
reach protocols do not exceed the
clinical scope of MA activities.24
Therefore, it was assumed that the
individual who conducted all out-
reach was paid at the same level as
an MA. Analyses incorporated an
assumed 25% fringe rate on top of
all hourly wages.
An uncertainty analysis was also
conducted that assumed lower per-
sonnel costs as a result of optimized
screening navigator workﬂows. Fol-
lowing completion of the prior
effectiveness trials, the authors
identiﬁed numerous opportunities
to streamline screening navigator
work, such as less frequent mailings
(i.e., once-a-month batching of FIT
kit mailings to patients who became
due for screening, rather than
weekly mailings) and reducing—or
eliminating—phone calls to patients
who had not completed FIT within
13 weeks, given the apparently
small yield of these calls.21,22 The
authors felt that under optimized
workﬂows, the screening navigator
would devote 30 minutes of out-reach work per patient due for screening.
Screening and cost projections were also made for three CHCs
whose patients’ CRC screening history differed from patients at the
base case organization (Table 1). In the ﬁrst alternative scenario, it
was assumed that a low (15%) proportion of CHC patients were
up-to-date on screening in the preceding year, but all other
assumptions from the base case were maintained. The other two
alternative scenarios assumed 60% of CHC patients were up-to-
date on CRC screening in the preceding year, matching a recent
estimate of the overall U.S. screening rate.10 A high rate of prior
FOBT use at one of these CHCs was assumed, whereby 90% of
prior screening was via FOBT (i.e., 54% of all screening-eligible
patients) and 10% of prior screening was via colonoscopy (i.e., 6%
of all screening-eligible patients). At the other CHC with 60% of
patients up-to-date in the prior year, it was assumed that 90% of
prior screening was via colonoscopy and 10% via FOBT.
Hypothetical revenues were additionally calculated in a ﬁctional
scenario where CHCs were paid on a fee-for-service basis for
completed FITs. Appendix 2 (available online) presents further
details on traditional differences between CHCs and fee-for-
service practices, and the methods used in revenue projections.Results
Compared with POC distribution of FIT kits, projected
CRC screening rates at the base case CHC were sub-
stantially higher in the outreach program, but at a much
Table 2. Data Used to Calculate Costs of Point-of-Care and Outreach Programs
Screening program components Base case cost, $ Sources
Point-of-care distribution
FIT kit 5.03 per mailing Medex Supply23
Print materials 0.60 per mailing See text
Return postage 1.44 per mailing See text
Stool specimen processing 2.20 per returned FIT Assumption: 6.5 minutes of lab technician effort
MA effort 0.58 per patient Assumption: 2.0 minutes of MA effort
Outreach
Initial mailing
FIT kit 5.03 per mailing Medex Supply23
Print materials 0.75 per mailing See text
Outgoing/return postage 3.36 per mailing See text
Automated reminders 0.30 per patient See text
Automated reminders at 2 weeks 0.30 per patient See text
Second mailing at 13 weeks
FIT kit 5.03 per mailing Medex Supply23
Print materials 0.75 per mailing See text
Outgoing/return postage 3.36 per mailing See text
Stool specimen processing 2.20 per returned FIT Assumption: 6.5 minutes of lab technician effort
FIT results letter
Print materials 0.30 per negative result See text
Outgoing postage 0.48 per negative result See text
MA effort 16.18 per patient
(range 8.75–16.18)
Assumption: 55.5 minutes of MA effort
(lower 30 minutes)
FIT, fecal immunochemical test; MA, medical assistant.
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due for screening would complete FIT under POC
distribution over 1 year, whereas 42.4% of patients due
for screening would complete FIT under outreach (18.4%
absolute difference). The projected proportion of patients
up-to-date on screening after 1 year—including those
up-to-date via prior colonoscopy—was 41.7% for POC
distribution and 55.8% for outreach (14.1% absolute
difference). On a per-patient basis, outreach cost $25.50
more than POC distribution ($30.43 vs $4.93), largely
because of MA effort costs that were $15.75 higher
($16.18 vs $0.43). The cost per patient screened was also
much higher for outreach than for POC distribution
($71.84 vs $20.60, $51.24 difference). The projected total
organizational cost over 1 year was $3,779 for POC
distribution and $23,315 for outreach ($19,536 difference).
In uncertainty analysis, decreased personnel costs led to a
sizable decrease in the cost of outreach. Compared withoriginal base case projections, outreach costs decreased by
approximately one fourth under optimized outreach work-
ﬂows, both in terms of cost per patient screened (Appendix 1,
Figure A1 [available online]) and total organizational cost
(Appendix 1, Figure A2 [available online]).
Screening and cost projections for other CHCs were
largely similar to base case projections, but outreach was
particularly effective at the CHC with high prior FOBT
use (Appendix 1, Table A1 [available online]). Because
54% of screening-eligible patients at the CHC with high
prior FOBT use were due for repeat annual screening—
and these patients have particularly high rates of FIT
completion via outreach22—this CHC had the highest
screening rate among patients due for screening (65.9%)
and lowest cost per patient screened ($45.14) in outreach
projections. At all three alternative CHCs, the projected
cost per patient due for screening only differed margin-
ally (i.e., o$1) from base case projections for eachwww.ajpmonline.org
Table 3. Projected Screening and Costs Over 1 Year for FIT Screening Programs at Base Case CHC
Base case outcomesa Point-of-care distribution Outreach Difference
Projected screening rates (%)
Proportion of patients due for screening who complete FITb 24.0 42.4 18.4
Proportion up-to-date on colorectal cancer screening 41.7 55.8 14.1
Projected costs ($)
Cost per patient due for screening 4.93 30.43 25.50
Cost per patient screened via FIT 20.60 71.84 51.24
Total organizational cost 3,779 23,315 19,536
aWe assumed that the base case CHC served 1,000 screening-eligible patients, 766 of whom were due for screening over 1 year and 234 of whom
remained up-to-date due to prior colonoscopy.
bCalculations exclude patients who are up-to-date on screening due to prior colonoscopy.
CHC, community health center; FIT, fecal immunochemical test.
Liss et al / Am J Prev Med 2016;50(2):e54–e61e59respective screening program. The CHC with high prior
colonoscopy had the lowest projected total organizational
cost ($2,573 for POC distribution, $15,600 for outreach)
because of the high proportion of patients who remained
up-to-date via prior colonoscopy (these patients would not
be targeted in either screening program).
In a hypothetical scenario assuming CHCs receive fee-
for-service reimbursement for completed FIT, projected
revenues were higher for outreach than POC distribu-
tion, but not nearly enough to compensate for the
additional cost of outreach (Appendix 2, Table A2
[available online]). These results were consistent across
different levels of assumed insurance coverage.
Discussion
After 1 year of a FIT outreach program, the projected
CRC screening rate at three of four hypothetical CHCs
was similar to the overall U.S. rate of 60%. In the POC
distribution program, the projected screening rate was at
least 10% less than that of outreach. However, the
outreach program costs substantially more than POC,
both overall and in terms of cost per patient screened.
This budget impact analysis demonstrates that out-
reach is a practical and relatively low-cost CRC screening
strategy. In simulations based on prior randomized trials,
the cost per completed FIT via outreach ranged between
$45.14 and $74.29, and screening costs were higher in
CHCs with more patients who had never screened. If
outreach programs are in place for multiple years, the
authors expect the cost per patient screened would
incrementally decrease each year as more patients who
had never previously screened initiate an annual FIT
regimen (i.e., transition from “never screened” status to
being due for repeat annual FIT).February 2016Expected costs of FIT outreach compare favorably to
costs of colonoscopy. In a Colorado program that
provided free colonoscopy to uninsured patients, medical
services cost $998 per patient and navigation to colono-
scopy cost $185 per patient ($1,183 combined).25 If these
cost estimates were applied to a screening program that
delivers colonoscopy every 10 years, colonoscopy would
cost about $118 per year, far exceeding FIT outreach.
However, current cost and revenue structures gener-
ally disincentivize outreach programs at CHCs.26 Even if
FIT outreach is globally cost saving compared with
colonoscopy, many CHCs will probably be unable to
pay for outreach. These organizations may therefore
need to continue to rely on POC strategies, despite the
relatively low effectiveness of this approach to screening.
Findings from the authors’ prior work21,22 and this
study’s uncertainty analysis show that outreach costs
could be further reduced by automating or eliminating
some outreach navigator tasks. CHCs could pursue
several approaches to optimizing navigator work
while making only a small impact on screening rates,
such as:1. Using POC strategies for patients who have never
screened, given the relatively small effect of outreach
in this group
21;
2. waiting an additional 3 months to deliver outreach to
patients due for repeat screening (i.e., 15 months since
the most recent FIT), as many of these patients already
receive FIT at in-person clinic visits around the time
of their annual due date for FIT22; or3. establishing partnerships with private laboratories
(which can bill insurers on a fee-for-service basis),
thus shifting some outreach costs to other
organizations.
Liss et al / Am J Prev Med 2016;50(2):e54–e61 e60These changes could substantially decrease required
navigator effort, potentially resulting in even less than 30
minutes of navigator work per patient.
Limitations
This analysis has several limitations. First, randomized
trial data used for projections were collected from one
CHC that had had a POC distribution program in place
for several years.19 Because it would probably take several
months to standardize POC workﬂows to the degree
achieved at the CHC where these trials were conducted,
the 1-year screening estimates for the POC program may
be high. Second, the authors assumed that patients who
were due for screening following prior colonoscopy
completed FIT at the same rate as patients who had
never screened. As completion of prior colonoscopy
demonstrates a willingness to undergo an invasive form
of CRC screening, for these patients the estimated
screening rate is probably low, while the estimated cost
per patient screened is probably high. Third, this study
did not include costs of primary care provider effort in
the POC program, even though providers probably need
to address issues that arise when patients receive MA
counseling during in-person visits. Fourth, the authors
did not include costs of navigation to diagnostic colono-
scopy following a positive FIT result, which apply to both
outreach and POC strategies. At the organization in
which the prior outreach trials were conducted, patients
with positive FIT results are navigated to offsite diag-
nostic colonoscopy through a separate program beyond
the scope of outreach navigator work. Although this
program was not included in the current study’s simu-
lations, it is crucial that diagnostic colonoscopy is
prioritized in FOBT screening programs. Fifth, the
uncertainty analysis investigating decreased personnel
costs assumed screening rates would not change as a
result of optimized navigator workﬂows. If elements of
the outreach program, such as phone calls to patients
who had not completed FIT within 13 weeks, are
removed or replaced with low-cost alternatives (e.g.,
additional automated reminders), screening rates in the
outreach group could be affected.
Conclusions
Outreach is highly effective and has the potential to
reduce disparities in CRC screening. However, outreach
has signiﬁcant attendant costs that may be problematic
for CHCs. POC strategies are much less expensive than
outreach, but will not allow CHCs to increase screening
rates to the same level as the broader U.S. population.
New funding streams will probably be needed to
make outreach ﬁscally feasible for CHCs. Potentialopportunities to explore include supplements to visit-
based reimbursement, quality bonus payments within
patient-centered medical homes or accountable care
organizations, and other incentives to maximize CRC
screening and overall clinical preventive service delivery.
Funding support was provided by the Agency for Healthcare
Research and Quality (P01 HS021141).
No ﬁnancial disclosures were reported by the authors of
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